Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

A. Drilon, G. R. Oxnard, D. S.W. Tan, H. H.F. Loong, M. Johnson, J. Gainor, C. E. McCoach, O. Gautschi, B. Besse, B. C. Cho, N. Peled, J. Weiss, Y. J. Kim, Y. Ohe, M. Nishio, K. Park, J. Patel, T. Seto, T. Sakamoto, E. RosenM. H. Shah, F. Barlesi, P. A. Cassier, L. Bazhenova, F. De Braud, E. Garralda, V. Velcheti, M. Satouchi, K. Ohashi, N. A. Pennell, K. L. Reckamp, G. K. Dy, J. Wolf, B. Solomon, G. Falchook, K. Ebata, M. Nguyen, B. Nair, E. Y. Zhu, L. Yang, X. Huang, E. Olek, S. M. Rothenberg, K. Goto, V. Subbiah, A. Drilon

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    544 Citations (Scopus)

    Résumé

    BACKGROUND RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event. CONCLUSIONS Selpercatinib had durable efficacy, including intracranial activity, with mainly lowgrade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

    langue originaleAnglais
    Pages (de - à)813-824
    Nombre de pages12
    journalNew England Journal of Medicine
    Volume383
    Numéro de publication9
    Les DOIs
    étatPublié - 27 août 2020

    Contient cette citation